SCHEMBL17893810

SCHEMBL17893810

Brc1ccc(C2(c3nc(-c4ccccc4)nc(-c4ccccc4)n3)c3ccccc3-c3ccccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ OPRK1 P41145 1/20 0.44
▸ NR1H4 Q96RI1 1/20 0.40
▸ NFKB1 P19838 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NFKB2 Q00653 2/20 0.38
▸ RELA Q04206 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ NR1H2 P55055 5/20 0.38
▸ NR1H3 Q13133 5/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ ABCG2 Q9UNQ0 2/20 0.37
▸ CYP1A1 P04798 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP1B1 Q16678 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1168392 0.84 L3MBTL1 (0.45) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL17893795 0.83 MEN1 (0.41) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL17899967 0.82 MAPT (0.41) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL17893687 0.81 NR1H4 (0.35) SMN1; SMN2MEN1KMT2ANR1H4NFKB1
SCHEMBL26728954 0.81 L3MBTL1 (0.42) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL26728812 0.81 L3MBTL1 (0.42) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL20127207 0.81 MEN1 (0.56) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL21394268 0.80 MEN1 (0.55) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL21394247 0.80 MEN1 (0.55) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL21394333 0.80 MEN1 (0.55) SMN1; SMN2MAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180002597-A1 Fluorene Derivatives as Light Emitting Elements for Electroluminescent Devices U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2018-01-04 — — US disclosed
EP-3240856-A1 FLUORENE DERIVATIVES AS LIGHT EMITTING ELEMENTS FOR ELECTROLUMINESCENT DEVICES Dow Global Technologies LLC (US) 2017-11-08 — — EP disclosed
WO-2016109274-A1 FLUORENE DERIVATIVES AS LIGHT EMITTING ELEMENTS FOR ELECTROLUMINESCENT DEVICES DOW GLOBAL TECHNOLOGIES LLC (US) 2016-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002597-A1 Fluorene Derivatives as Light Emitting Elements for Electroluminescent Devices LEF1, AFF2, CELF2 SMN1; SMN2 3267/4885MAPT 3724/4885MEN1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback